Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923702 | 0.87 | L3MBTL1 (0.49) | DRD3L3MBTL1KDM4EALDH1A1BACE1 | |
| SCHEMBL4925910 | 0.83 | DRD3 (0.51) | DRD3HRH3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL4928989 | 0.82 | L3MBTL1 (0.56) | DRD3L3MBTL1KDM4EALDH1A1BACE1 | |
| SCHEMBL4923558 | 0.82 | ALDH1A1 (0.52) | DRD3L3MBTL1KDM4EALDH1A1ACHE | |
| SCHEMBL4930910 | 0.81 | ACHE (0.62) | DRD3HRH3L3MBTL1ALDH1A1ACHE | |
| SCHEMBL4925214 | 0.80 | DRD3 (0.60) | DRD3HRH3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL4922627 | 0.73 | DRD3 (0.63) | DRD3HRH3ACHETDP1CYP2D6 | |
| SCHEMBL9764367 | 0.72 | HTR2C (0.43) | L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL791880 | 0.72 | DRD3 (0.61) | DRD3HRH3ACHETDP1CYP2D6 | |
| SCHEMBL9803079 | 0.71 | CHRM2 (0.44) | KDM4ECACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | DRD3 2434/4885HRH3 2081/4885L3MBTL1 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.